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Omega-3, omega-6 and polyunsaturated fat for cognition: systematic 1 
review & meta-analysis of randomised trials 2 
 3 
 4 
Structured Abstract  5 
Objectives: Neurocognitive function may be influenced by polyunsaturated fat intake.  Many 6 
older adults consume omega-3 supplements hoping to prevent cognitive decline.  We 7 
assessed effects of increasing omega-3, omega-6 or total polyunsaturated fats on new 8 
neurocognitive illness and cognition.  9 
 10 
Design and inclusion criteria: We carried out a systematic review and meta-analysis of 11 
randomised controlled trials in adults, with duration  ≥24 weeks, assessing effects of higher 12 
vs lower omega-3, omega-6 or total polyunsaturated fats and outcomes: new neurocognitive 13 
illness, newly impaired cognition, and/or continuous measures of cognition.   14 
 15 
Methods: We searched Medline, Embase, Cochrane CENTRAL and trials registers (final 16 
update of ongoing trials December 2018). We duplicated screening, data extraction and risk 17 
of bias assessment.  Neurocognitive measures were grouped to enable random-effects meta-18 
analysis.  GRADE assessment, sensitivity analyses and subgrouping by dose, duration, type 19 
of intervention and replacement were used to interrogate our findings.   20 
 21 
Results: Searches generated 37,810 hits, from which we included 38 RCTs (41 comparisons, 22 
49,757 participants).  Meta-analysis suggested no or very little effect of long-chain omega-3 23 
on new neurocognitive illness (RR 0.98, 95% CI 0.87 to 1.10, 6 RCTs, 33,496 participants, I2 24 
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36%), new cognitive impairment (RR 0.99, 95% CI 0.92 to 1.06, 5 RCTs, 33,296 25 
participants, I2 0%) or global cognition assessed using the Mini-Mental State Examination 26 
(MD 0.10, 95% CI 0.03 to 0.16, 13 RCTs, 14,851 participants, I2 0%), all moderate-quality 27 
evidence. Effects did not differ with sensitivity analyses, we found no differential effects by 28 
dose, duration, intervention type or replacement.  Effects of increasing ALA, omega-6 or 29 
total PUFA were unclear.  30 
 31 
Conclusions: This extensive trial dataset enabled assessment of effects on neurocognitive 32 
illness and cognitive decline not previously adequately assessed.  Long-chain omega-3 33 
probably has little or no effect on new neurocognitive outcomes or cognitive impairment. 34 
 35 
Implications: Long-chain omega-3 supplements do not help older adults protect against 36 
cognitive decline.  37 
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Introduction   38 
 39 
Older adults, including those living in long-term care, are at high risk of cognitive 40 
impairment, and neurocognitive ill-health.1-3  Fifty million people worldwide were living 41 
with dementia in 2018, a number predicted to rise to 152 million in 2050.4 Neurocognitive 42 
disorders, including dementias, are major causes of health and social care cost, disability 43 
adjusted life years and mortality worldwide.5-7  Dementia costs worldwide are one trillion US 44 
dollars annually and rising, with 66% of new cases in low- and middle-income countries.4 45 
 46 
There is keen interest in potential cognitive protection offered by polyunsaturated fats, 47 
particularly omega-3,8-10 which is one of the most common dietary supplements.  US adults’ 48 
long-chain omega-3 intakes are greater from dietary supplements (0.72 g/d EPA and DHA) 49 
than foods (0.41 g/d).11  Polyunsaturated fatty acids, especially docosahexaenoic acid (DHA, 50 
one of the long-chain omega-3 fats, found in oily fish and arachidonic acid, an omega-6), are 51 
key structural components of the brain and central nervous system and may help maintain 52 
membrane integrity and neuronal function.9 DHA may also be neuroprotective via anti-53 
inflammatory mechanisms, competing with pro-inflammatory omega-6.9 These mechanisms 54 
suggest that long-chain omega-3 fats (LCn3) may be protective, and omega-6 fats neutral or 55 
harmful, to cognition.  56 
 57 
However, LCn3 supplements (though not ALA) may harm neurocognition by another 58 
mechanism. Marine-origin foods and LCn3 supplements are at risk of contamination by 59 
heavy metals, organochlorines, polychlorinated biphenyls (PCBs) and polycyclic aromatic 60 
hydrocarbons (PAHs), all known to harm human health.12, 13  Possible impacts on human 61 
health from ingesting unsafe levels of PCBs and/or methyl mercury include reduced cognitive 62 
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function and neurological disorders.13, 14  Systematic reviews of observational data suggest 63 
higher omega-3 intake,15 and higher omega-3 to omega-6 ratio, are associated with better 64 
cognition.16  However, reverse causation and confounding by other lifestyle factors are 65 
feasible and could explain such relationships even in the absence of health benefits from 66 
increasing omega-3 intakes; for example poor cognition may lead to poorer quality dietary 67 
intake.  68 
 69 
A 2012 Cochrane review assessed effects of omega-3 fats on neuro-cognition.  That review 70 
found no trials of incident dementia and included three RCTs assessing effects on cognition, 71 
concluding that longer studies were required to allow time for greater cognitive changes to 72 
occur.17 Our review aimed to systematically review effects of higher vs lower intakes of 73 
LCn3, alpha-linolenic acid (ALA), omega-6 and total polyunsaturated fatty acids (PUFA) on 74 
new neurocognitive outcomes, new impaired cognition, and cognitive function in randomised 75 
controlled trials (RCTs) of at least 6 months duration. This review was commissioned to 76 
inform the development of World Health Organization (WHO) guidance on polyunsaturated 77 
fatty acid intake. 78 
 79 
  80 
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Methods 81 
This systematic review and meta-analysis is one of a series assessing health effects of omega-82 
3, omega-6 and total PUFA,18-26 its protocol was registered on PROSPERO 83 
(CRD42017019049). Detailed methods for the review series are reported elsewhere,23 and 84 
briefly summarised for this review below. 85 
 86 
We included randomised controlled trials (RCTs) that compared higher versus lower omega-87 
3, omega-6 and/or total PUFA intakes in adults (18+ years, not pregnant or seriously ill) with 88 
or without current or previous diagnosis of any type of neurocognitive illness or impairment, 89 
unlimited by language, publication type or publication date. The intervention could consist of 90 
foodstuffs, oral supplements (oil, capsules, or provided foodstuffs) or advice that increased or 91 
decreased omega-3, omega-6 and/or total PUFA intake, or (if no specific aim was stated) 92 
achieved a change of ≥10% of baseline intake. Studies were excluded if they carried out 93 
multiple risk factor interventions on lifestyle or dietary factors other than PUFA. 94 
Interventions to raise or lower PUFA intake had to be compared with usual diet, no advice, 95 
no supplementation or placebo (as appropriate), or compared raised versus lowered PUFA 96 
intake.  Trial duration minimum was 24 weeks, which reflects metabolic studies suggesting 6 97 
months is the minimum duration of supplementation required to ensure equilibration of LCn3 98 
into most body compartments, including the brain.27  Studies were included if they collected 99 
data on any primary outcome, even if study objectives were not primarily neuro-cognitive. 100 
Primary outcomes were new neurocognitive illness, newly impaired cognition, global 101 
cognition, executive function, processing speed and memory (including verbal, spatial and 102 
other memory and attention).  103 
 104 
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We searched Cochrane CENTRAL, Medline and Embase to 27th April 2017, 105 
ClinicalTrials.com and the World Health Organization International Clinical Trials Registry 106 
Platform to September 2016, and reassessed all ongoing trials in December 2018. We 107 
checked included trials of relevant systematic reviews, and wrote to authors of included 108 
studies for additional studies and trial data (including unpublished summary outcome data). 109 
See methods paper for detailed search strategies.23 110 
 111 
Study inclusion, data extraction and assessment of risk of bias (on a specially developed 112 
form) were conducted independently in duplicate. We extracted study-level data and assessed 113 
Cochrane risk of bias domains plus risk from compliance problems and attention bias.23, 28 114 
We considered trials to be at low summary risk of bias where we judged randomisation, 115 
allocation concealment, blinding of participants, personnel and outcome assessors adequate 116 
(all other trials were considered at moderate or high risk of bias).  117 
 118 
Analysis and Interpretation 119 
Main analyses assessed effects of omega-6, LCn3, ALA and total PUFA interventions on 120 
primary outcomes using random effects meta-analysis with risk ratio or mean differences in 121 
Review Manager version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark).29 Pre-122 
specified sensitivity analyses included fixed effects analysis, limiting analysis to studies at 123 
low summary risk of bias, limiting to studies at low risk for compliance issues, and limiting 124 
to trials randomising at least 100 participants. Pre-specified subgroup analysis was conducted 125 
for outcomes with at least 10 included studies to assess whether effects differed by 126 
intervention type (dietary advice, supplementary capsules, supplementary foods or a 127 
combination), replacement, dose, duration, baseline dementia (primary prevention where 128 
<50% diagnosed with cognitive problems, secondary prevention where ≥50% diagnosed with 129 
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cognitive problems) and anti-dementia medication use in ≥50% participants.23 We planned to 130 
sub-group by number of anti-dementia medications used, baseline intake of omega-3, omega-131 
6 or total PUFA, and omega-3/omega-6 ratio, but this information was not available in most 132 
trials so was not attempted. We assessed heterogeneity between trials using I2, and small 133 
study bias using funnel plots and knowledge of missing data.30 134 
 135 
Because of the diversity of metrics used to measure cognitive function, pooled analysis was 136 
often only possible by grouping similar measures. We standardised groupings by adopting 137 
neurocognitive domains suggested by others,31-33 placing data in a domain (and subdomain) 138 
by researching the derivation, purpose and supported interpretation for each metric (Table 1). 139 
The direction of scales in forest plots was standardised so that a lower score signified lower 140 
levels of cognitive ability and different scales were combined meta-analytically using 141 
standardised mean differences. Within each cognitive domain we ordered tests so that the 142 
best, most commonly used and most immediate tests were higher in Table 1. Outcomes were 143 
preferred in this order in forest plots: thus, if a single study reported several tests within a 144 
single domain all test results were displayed in the forest plot but only the first results for that 145 
study (those nearest the top of the forest plot and Table 1) were pooled in meta-analysis, 146 
ensuring that the most useful tests had as much available data as possible.  Data from 147 
individual participants were never counted more than once in any single meta-analytical 148 
pooling.  149 
 150 
Effect sizes were interpreted as agreed with  the World Health Organization (WHO) Nutrition 151 
Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health and pre-specified 152 
for this set of reviews23.  RR <0.92 or >1.08 was considered a relevant clinical effect (RR 153 
0.92 to 1.08 was considered “little or no effect”), while a mean difference between arms of 154 
SR of omega-3, omega-6 & total PUFA for cognition, page 8 
 
≥5% of baseline was required for a relevant clinical effect for continuous measures. Outcome 155 
data were interpreted using GRADE assessment,23  Where GRADE suggested data of very 156 
low-quality we did not interpret effect sizes.  Where data were of low-quality we used the 157 
term “may”, moderate-quality evidence warranted “probably” in describing effects.  158 
 159 
WHO funded the research, and the WHO NUGAG Subgroup on Diet and Health was 160 
involved in its design, but not in data collection, analysis, interpretation or the decision to 161 
publish. The exception is that GRADE assessment was drafted by LH then discussed and 162 
agreed with NUGAG as part of guidance development. All researchers had full access to all 163 
the data (within a shared database) and take responsibility for the accuracy and integrity of 164 
the data. 165 
 166 
  167 
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Results 168 
The broader search strategy for the full set of reviews generated 37,810 hits, de-duplicated to 169 
19,772 titles and abstracts from which 364 RCTs (reported in 1020 papers) of omega-3, 170 
omega-6 or total PUFA with a duration of at least 24 weeks were found.23 From this set of 171 
trials we included 38 RCTs (41 comparisons, including 49,757 participants) that assessed 172 
outcomes of interest to this review (see Figure 1 of our database paper for PRISMA 173 
flowchart;23 Table 2 in this paper presents brief characteristics of included RCTs). 174 
 175 
Trials were published from 1978 to 2018; only two did not take place in high income 176 
countries. Mean duration was 21 months. Thirty six comparisons compared higher with lower 177 
LCn3, two compared higher with lower ALA34-36, 1 omega-637, one total PUFA38-40 and one 178 
increased both omega-6 and total PUFA41. All trials were of capsular supplements except for 179 
four LCn3 trials (one of supplementary margarine34, 35, one of advice to eat more oily fish 41, 180 
and two providing fish sausages42, 43), both ALA trials (supplementary margarine34, 35 and 181 
yogurt with added canola36), the omega-6 trials (provided emulsified oil37 or advice to 182 
increase specific oils and margarines41) and total PUFA trial (dietary advice plus oil or nut 183 
supplements38-40). LCn3 doses ranged from 150mg/day to 4.4 g/day, but most were in the 184 
range 400-2400 mg/d (Table 2). Participants included people with normal and impaired 185 
cognition at baseline. Fifteen comparisons were at low summary risk of bias, see Figure 1 for 186 
risk of bias assessments by trial and domain. Key findings are summarised here, results are 187 
presented in full with references, forest plots and GRADE assessments in the Appendix. 188 
 189 
Six RCTs reported adverse neurological outcomes, including dementia, low cognitive 190 
function, neurological hospitalisation and motor neurone disease41, 44-48. Meta-analyses 191 
suggested that increasing LCn3 had little or no effect on new neurocognitive diagnosis (RR 192 
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0.98, 95% CI 0.87 to 1.10, I2 36%, >33,000 participants of whom 2622 developed a 193 
neurocognitive illness, moderate-quality evidence) and little or no effect on new cognitive 194 
impairment (RR 0.99, 95% CI 0.2 to 1.06, I2 0%, >33,000 participants of whom 2551 195 
developed impaired cognition, moderate-quality evidence), Figure 2. This lack of effect did 196 
not alter in sensitivity analyses or when subgrouping by dose, duration or replacement by 197 
LCn3 of other nutrients.  198 
 199 
Nineteen trials provided assessment of LCn3 on global cognition using at least one scale, 200 
including >20,000 participants for ≥6 months, in people with normal cognition to moderate 201 
dementia at baseline. Effects in the 11 different scales provided different answers (test for 202 
subgroup differences p<0.00001), so we ran our assessment including 13 trials (14,851 203 
participants) using Mini-Mental State Examination (MMSE, which runs from 0, very poor 204 
cognition, to 30, or normal cognition 49). Increasing LCn3 led to a very small improvement in 205 
MMSE, altering it by <1% of baseline (MD 0.10, 95% CI 0.03 to 0.16, I2 0%, Figure 3, 206 
unaltered in sensitivity analyses, moderate-quality evidence), but we are aware of high levels 207 
of missing data and the funnel plot suggested small study bias (Figure A2 in the Appendix). 208 
If we added small studies to correct this bias we would move the MD closer to zero (no 209 
effect). Subgrouping did not suggest differences in effect by LCn3 dose, duration, 210 
replacement (of MUFA, omega-6 or non-fat), intervention type (supplemental foods or 211 
capsules), baseline cognitive status (normal or impaired cognition), or cognitive medication 212 
use.  213 
 214 
Six trials (including 1757 participants) assessed executive function, five trials (including 215 
1426 participants) assessed effects of LCn3 on processing speed, and eleven (including 5698 216 
participants) assessed memory. Meta-analysis suggested little or no effect for all of these 217 
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measures (as well as the sub-categories of memory, all moderate- or low-quality evidence, 218 
see Appendix for further information).  219 
 220 
We found no trials assessing effects of ALA on new neurocognitive outcomes or cognitive 221 
decline, executive function, processing speed or any type of memory. Two trials assessed 222 
effects of ALA on global cognition, the ALA assessment in Alpha-Omega (assessing MMSE 223 
in 2522 participants) and Rebello (measuring ADAS-Cog in 4 participants at study end).34, 36 224 
As Rebello was so small we did not combine these data and use SMD. Alpha-Omega 225 
suggested little or no effect of increasing ALA on MMSE (MD 0.14, 95% CI -0.03 to 0.31, a 226 
change of 1% from baseline MMSE, low-quality evidence).  227 
 228 
Only one RCT noted new cognitive outcomes following two years of omega-6 intervention in 229 
2033 men, reporting 2 cases of dementia and 5 of motor neurone disease, insufficient data on 230 
which to assess health effects. One small trial increased omega-6 and assessed global 231 
cognition (EDSS mentation), but did not provide any measure of variance so statistical 232 
significance was unclear. We found no trials of omega-6 reporting executive function, 233 
processing speed, verbal, spatial or other memory, or attention.  234 
 235 
Two RCTs noted new neurocognitive outcomes following ≥2 years of increased PUFA, 236 
including 20 cases of dementia, 62 of mild cognitive impairment and 5 of motor neurone 237 
disease. Effects of increasing PUFA on new neurocognitive diagnosis were unclear as the 238 
evidence was of very low-quality. Two cohorts of a single large trial (PREDIMED) assessed 239 
global cognition using the MMSE in a subset (629) of participants. Effects of increasing 240 
PUFA on global cognition was unclear as the evidence was of very low quality while the 241 
effect size was <1% of baseline, MMSE MD -0.14, 95% CI -0.44 to 0.16. Some PREDIMED 242 
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participants were assessed for verbal memory, spatial memory and executive function. Data 243 
were limited from this trial, which was at moderate to high summary risk of bias, suggesting 244 
changes <5% of baseline for verbal memory and executive function. However, there was a 245 
larger change in spatial memory, suggesting an improvement in spatial memory with more 246 
PUFA (assessed using the Color Trail Test part 1, MD 7.17, 95% CI 0.48 to 13.86, I2 0%). 247 
No trials assessed effects of increasing total PUFA on processing speed.  248 
 249 
 250 
  251 
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Discussion 252 
Increasing LCn3 probably has little or no effect on new neurocognitive outcomes, new 253 
impaired cognition, global cognition, executive function, processing speed or memory. 254 
Increasing ALA may have little or no effect on global cognition, but we found no RCTs of 255 
ALA reporting other neurocognitive outcomes. The effects of increasing omega-6 or total 256 
PUFA on new neurocognitive outcomes, cognitive decline and global cognition, executive 257 
function, processing speed or memory are unclear.  258 
 259 
Recent systematic reviews have assessed effects of omega-3 fats on cognition in different 260 
ways, but all included many fewer RCTs than this review, limiting their ability to accurately 261 
assess effect sizes. Yurko-Mauro et al. reported significant between-group benefits for 262 
episodic memory after DHA supplementation, based on results reported in only five RCTs 263 
(describing <1000 participants).33  However, Yurko-Mauro et al. pooled all reported 264 
measures of episodic memory from each trial, which means that many, but not all, 265 
participants were included four or five times in a single meta-analyses.  This is statistically 266 
inappropriate as it over-counts effects in some participants.33 They did not find between-267 
group differences for semantic or working memory outcomes. Zhang et al. pooled data from 268 
six pre-2015 RCTs and found statistically significant but clinically unimportant differences in 269 
MMSE (WMD = 0.15; 95% CI: 0.04-0.26; p = 0.006), results similar to this review.50 It was 270 
unclear why they used WMD (rather than MD) to combine the single scale. Both Yurko-271 
Mauro et al. and Zhang et al. included short RCTs (<24 weeks duration) ineligible for our 272 
review and less able to accurately assess changes in cognition over time than longer trials.  A 273 
2013 systematic review of nutritional interventions for Alzheimer’s Disease suggested that 274 
long-chain omega-3 supplementation improved verbal fluency (in two small trials), might 275 
support cognition in very mild AD (in one trial) but did not alter neuropsychiatric symptoms, 276 
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delay the rate of cognitive decline, or affect memory, global cognition or brain volume (each 277 
in individual trials).51 A 2017 network meta-analysis assessing the utility of nutritional 278 
strategies in managing Alzheimer’s Disease included six trials of omega-352-54 ranked omega-279 
3 as the worst of their nutritional interventions (the efficacy of omega-3 was compared with 280 
antioxidants, B-vitamins, inositol, medium-chain triglyceride, polymeric formulas, 281 
polypeptide, and vitamin D).55 A 2018 systematic review of RCTs by Butler et al. assessing 282 
effects of over-the-counter nutritional supplements found insufficient evidence to recommend 283 
any supplement for cognitive protection in adults (including omega-3).56 That review 284 
included only 9 trials compared to our 38 RCTs. A recent Cochrane review of effects of 285 
omega-3 for treatment of dementia found only three RCTs and no convincing evidence of 286 
beneficial effects on cognition or quality of life.57   287 
 288 
We found statistically significant but clinically unimportant effects of LCn3 on MMSE 289 
scores, differing by <1% of baseline.  The MMSE asks verbal questions to detect impaired 290 
thinking and was developed, and is most validated, for dementia screening.58 The three trials 291 
contributing 94% of the weight to this analysis included 13,503 participants and were all of at 292 
least 3 years duration.  The largest was 6 years long, suggesting that the reason for the small 293 
effect size was not that trials were too short or too small.  Doses of LCn3 were 0.40, 0.84 and 294 
1.04g/d, 0.84/d in the largest single RCT.  Eating three portions of fish per week, one of 295 
which is oily (current healthy eating advice), provides approximately 0.4g/d LCn3.  Data on 296 
effects of LCn3 will be strengthened with publication of VITAL-Cog, which randomised 297 
almost 4000 participants aged 60+ years for 5 years with a primary outcome of change in 298 
cognitive function.59 VITAL cardiovascular outcomes were published in late 2018, but 299 
cognitive outcomes are not expected until late 2020. 300 
 301 
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We used subgrouping to assess whether effects differed according to whether supplementary 302 
capsules, foods rich in specific PUFAs or foods supplemented with specific PUFAs were 303 
provided.  There were no suggestions that effects of foods were different from those of 304 
capsules, but as most trials were of capsules there was little power to assess differential 305 
effects. As effects would be greater when omega-6 is replaced by LCn3 if the omega-3 to 306 
omega-6 ratio theory is important, we also assessed whether effects differed by replacement 307 
(see for example Figure A4), but no important differences were observed. We did not find 308 
different effects in trials of higher LCn3 doses or of longer durations, as noted in the 309 
Appendix page 3, as would be expected if some included trials are too short or of too low a 310 
dose. 311 
 312 
We were interested in both potential benefits and harms, and found moderate-quality 313 
evidence of little or no effect of LCn3 on neurocognitive outcomes or cognitive ability.  We 314 
found neither benefits nor harms, and low-quality evidence of little or no effect of ALA on 315 
global cognition.  Evidence of any effect of ALA, omega-6 and total PUFA on 316 
neurocognitive outcomes and cognition are lacking.  Other potential reasons for increasing 317 
polyunsaturated fat intake, including effects on cardiovascular diseases, cancers, 318 
inflammatory bowel disease, body weight, diabetes and glucose metabolism, depression and 319 
anxiety and all-cause mortality, have been considered elsewhere in our series of systematic 320 
reviews.18-20, 23, 60-64 321 
 322 
We devised domains to group similar metrics and undertake pooled analysis building on 323 
previous literature; however, our groups are not definitive.  We did not set out to devise an 324 
authoritative logic model for to group neurocognitive measures. Any such grouping is likely 325 
to be imperfect.  While alternative clustering or order of neurocognitive measures may have 326 
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yielded slightly different numerical summaries, the lack of clinical effect from PUFA 327 
interventions that we report is consistent across many different measures. We have tried to be 328 
transparent about the statistical significance of individual measures as reported in the original 329 
studies (see Tables and Figures in the Appendix), as well as the rationale used when pooling 330 
similar measures, to look for possible effects of LCn3, ALA, omega-6 and total PUFA. 331 
 332 
Conclusions and implications 333 
People concerned about their cognitive health should be advised that taking long-chain 334 
omega-3 supplements is not helpful for cognition, but neither is it harmful.  No further trials 335 
of supplementary LCn3 should be initiated until VITAL-COG has reported, but 336 
methodologically strong and long duration trials of increased oily fish intake, nuts and foods 337 
high in ALA, and increased omega-6 and total PUFA intake are needed to further inform 338 
dietary advice for cognition. 339 
 340 
Ethical approval: No ethical approval was required.    341 
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Figure titles 603 
 604 
Figure 1. Risk of bias assessment for each included trial by risk of bias domain 605 
 606 
Figure 2. Effects of increased LCn3 on neurocognitive outcomes individually and grouped, random 607 
effects meta-analysis.  608 
 609 
Figure 3. Effects of increased LCn3 on measures of global cognition, random effects meta-analysis. 610 
(Different measures not combined as the test for subgroup differences suggested severe heterogeneity 611 
between tests.)  612 
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  Dementia diagnosis 
 MCI (Mild cognitive impairment) 
 TICS (Telephone Interview for Cognitive Status), score <30 
 EDSS (Expanded Disability Status Scale), mentation change 
Global cognition    MMSE (Mini-Mental State Examination) 
 ADAS- Cog (Alzheimer’s Disease Assessment Scale – Cognitive 
subscale) 
 CDR (Clinical Dementia Rating scale) 
 CIBIC-Plus (Clinician’s Interview-Based Impression of Change 
with caregiver input) 
 HDS (Hasegawa Dementia Scale) 
 FTICS Score – French Telephone Interview for Cognitive Status  
 BCAT (Brief Cognitive Assessment Tool), total score, cognitive 
function 
 IQ (Intelligence Quotient) 
 Global brain volume change 
 Global cognitive function z-score (study-specific batteries) 
Executive function    Working memory – 2 back accuracy 
 Working memory – 2 back response time 
 BCAT working memory 
 BCAT mental arithmetic efficiency 
 SOC (Stockings of Cambridge) problem solved  
 Numeric working memory % accuracy 
 Digit Span Forward 
 Executive function z score (study-specific batteries) 
Memory  Verbal  
 
 CANTAB (Cambridge Neuropsychological Test Automated 
Battery), VRM (verbal recognition memory), immediate recall, 
total correct  
 CANTAB VRM, free recall, total correct 
 CVLT (California Verbal Learning Test) 
 RAVT (Rey Verbal Learning Test), immediate recall 
 CANTAB VRM, delayed recall, total correct 
 RAVT, delayed recall 
 Verbal Fluency  
Spatial 
 
 CANTAB SWM (spatial working memory), between errors 
 BCAT SIE (Space Imagery Efficiency)  
 CANTAB PRM (pattern recognition memory), delayed, number 
correct 
 Corsi blocks span score 
 Color Trail test part 1 
Attention 
 
 DSST (Digit symbol substitution test) 
 Stroop overall % accuracy 
 Attention z-score (study-specific batteries) 
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Others  MMSE, Memory section 
 Lexical Fluency 
 Memory Functioning, mean within group change 
 BCAT Recognition Memory 
 Memory z-score (study-specific batteries) 
Processing Speed 
 
  BCAT, perceptual speed  
 Stroop total correct RT 
 Processing speed z-score (study-specific batteries) 
* Not every test within each domain or outcome group was applied for every intervention 614 
  615 
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Table 2. Brief characteristics of, and references for, included studies. 
 
Study Participant 




Duration Country Comparison Number randomised Summary 
Risk of 
Bias Intervention Control 
ADCS-Quinn 
2010 65 
Mean 76 yrs Individuals with mild to 
moderate Alzheimer disease 
(I) 
18 m USA DHA vs. n6 238 164 Low 
Alpha-Omega 
ALA 34, 35 
60-80 yrs 60-80 year olds with 
previous MI (N) 
40 m Netherlands ALA vs. MUFA (1257) (1265) Low 
Alpha-Omega 
EPA+DHA 34, 35 
60-80 yrs  60-80 year olds with 
previous MI (N) 
40 m Netherlands EPA+DHA vs. 
MUFA 
1240 1282 Low 
AREDS 2 2014 
48, 66 
50-85 yrs  People at high risk of 
progression to advanced age-
related macular degeneration 
(N) 
5 yrs USA EPA+DHA vs. nil 2147 2056 Low 
ASCEND 2018 
44 
≥40 yrs People with diabetes, 
without apparent vascular 
disease (N) 
7.4 yrs UK EPA+DHA vs. 
MUFA 
7740 7740 Low 
Baleztena 2015 
67 
75 yrs + Institutionalised older adults 
without cognitive problems 
(N) 
1 yr Spain EPA+DHA vs. nil 49 49 MoH 
Bo 2017 68 ≥ 60 yrs Older adults with mild 
cognitive impairment (I) 
6 m China EPA+DHA vs. 
MUFA 
44 42 MoH 
Boespflug 2016 
69 
62-80 yrs Older adults with subjective 
memory impairment (I) 
6 m USA EPA+DHA vs. 
LA 
15 12 MoH 
Chiu 2008 70 70-81 yrs Older adults with 
Alzheimer's Disease or Mild 
Cognitive Impairment (I) 
6 m Taiwan EPA+DHA vs. 
MUFA 
24 22 MoH 
Chiu 2010 
(NCT01235533) 
60 yrs + Older people with Late-Life 
Depression (N) 
11 m Taiwan EPA+DHA vs. 
MUFA 
nr nr MoH 
DART 1989 
(fat) 41  
<70 yrs Men recovering from an MI 
(N) 
2 yrs UK n6 vs. mixed fats (1018) (1015) MoH 
DART 1989 
(fish) 41 
<70 yrs Men recovering from an MI 
(N) 
2 yrs UK EPA+DHA vs. nil 1015 1018 MoH 
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Study Participant 




Duration Country Comparison Number randomised Summary 
Risk of 
Bias Intervention Control 
EPOCH 2011 71 65-90 yrs Healthy older adults with no 
cognitive impairment (N) 
18 m Australia EPA+DHA vs. 
MUFA 
195 196 Low 
Hashimoto 
2012 43 
Mean 72.5 yrs Healthy older people (N) 1 yr Japan EPA+DHA vs. 
MUFA 
57 54 MoH 
Hashimoto 
2016 42 
Mean 88 yrs Healthy older people (N) 1 yr Japan high DHA vs. low 
DHA 
43 32 MoH 
Jackson 2016 72 Mean 60 yrs Healthy adults with 
subjective memory deficit 
(MMSE ≥26, MAC-Q score 
> 24) (I) 
6 m UK high DHA vs. low 
DHA+PUFA 
33 32 MoH 
Lee 2012 73 ≥60 yrs Elderly individuals living in 
low to middle 
socioeconomic public flats 
(N) 
1 yr Malaysia EPA+DHA vs. 
LA 
18 18 MoH 
MAPT 2017 74 ≥70 yrs People without dementia but 
with memory complaint, 
IADL limitation or slow gait 
speed (mixed) 




432 420 Low 
MEMO Van de 
Rest 2008 75 
≥ 65 yrs Independently living people 
(N) 
6 m Netherlands EPA+DHA vs. 
MUFA 
96 103 MoH 
MIDAS 2010 76 ≥ 55 yrs Healthy older people with 
subjective memory 
complaints (no dementia 
diagnosis) (I) 
24 wks USA EPA+DHA vs. 
LA 
242 243 Low 
Nutristroke    
Antiox 77 
Mean 65 yrs People who had survived a 
stroke (N) 
1 yr Italy EPA+DHA vs. nil 18 16 MoH 
Nutristroke No 
antiox 77 
Mean 65 yrs People who had survived a 
stroke (N) 




Mean 38.6 yrs People with relapsing 
remitting multiple sclerosis 
(N) 
6 m Norway EPA+DHA vs. 
LA 
46 46 MoH 
OmegAD 2008 
52-54 
Mean 73 yrs People with mild to 
moderate Alzheimer's 
disease (I) 
6 m Sweden EPA+DHA vs. 
LA 
103 101 MoH 
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Study Participant 




Duration Country Comparison Number randomised Summary 
Risk of 




70-79 yrs Healthy cognitively normal 
adults (N) 
2 yrs UK EPA+DHA vs. 
MUFA 
434 433 Low 
ORIGIN 2013 
80 
Mean 64 yrs People at high risk of CV 
events and impaired glucose 
metabolism (N) 
6 yrs Multiple EPA+DHA vs. 
MUFA 
6319 6292 Low 
Paty 1978 37 Mean 45 yrs Patients with multiple 
sclerosis (N) 
2.5 yrs Canada LA vs. MUFA 38 38 MoH 
Pomponi 2014 
81 
Mean 64 yrs Adults with mild to moderate 
Parkinson's disease (N) 
6 m Italy EPA+DHA vs. 
LA 
12 12 MoH 
PREDIMED 
2013 38-40 
Mean 67 yrs People with several CVD 
risk factors (N) 
56 m Spain high PUFA vs. 
low PUFA 
2454 2543 MoH 
Puri 2005 82 Mean 50 yrs People with Huntington's 
Disease (N) 
1 yr Multiple EPA vs. non-fat 67 68 Low 
Raitt 2005 46 Mean 62.5 yrs People with heart rhythm 
problems (N) 
2 yrs USA EPA+DHA vs. 
MUFA 
100 100 MoH 
Rebello 2015 36 58-78 yrs Healthy older people 24 wks USA ALA vs. mixed 
fats 
3 3 MoH 
Romero 2013 83 Mean 72.5 yrs People with mild cognitive 
impairment (I) 
6 m Spain EPA+DHA vs. nil 15 15 MoH 
Schattin 2016 84 Median 67 yrs Older adults (N) 26 wks Italy EPA+DHA vs. 
MUFA 
29 29 Low 
SCIMO Von 
Schacky 1999 47 
Mean 58 yrs People with coronary artery 
disease (N) 
2 yrs Germany EPA+DHA vs. 
mixed fats 
112 111 Low 
Shinto 2014 85 Mean 75.6 yrs People with probable 
Alzheimer dementia (I) 
1 yr USA EPA+DHA vs. 
LA 
13 13 MoH 
Sinn 2012 86 Mean 74.5 yrs Older people with mild 
cognitive impairment (I) 
6 m Australia EPA+DHA vs. 
LA 
18 18 Low 
Stonehouse 
2013 87 
Mean 33.3 yrs Healthy men and women (N) 6 m New 
Zealand 
DHA vs. MUFA 115 113 MoH 
SU.FOL.OM3 
Galan 2010 88-90 
Mean 61 yrs People with a history of 
CVD (N) 
4 yrs France EPA+DHA vs. 
non-fat 
1248 1253 Low 
SR of omega-3, omega-6 & total PUFA for cognition, page 29 
 
Study Participant 




Duration Country Comparison Number randomised Summary 
Risk of 
Bias Intervention Control 
Terano 1999 91 Mean 83 yrs Older adults living in a care 
home with mild to moderate 
dementia (I) 
1 yr Japan EPA+DHA vs. nil 10 10 MoH 
Zhang 2017 92 Mean 74.5 yrs Otherwise healthy elderly 
people with mild cognitive 
impairment (I) 
1 yr China EPA+DHA vs. 
LA 
120 120 MoH 
 
Total 38 RCTs, 
41 comparisons 




 36 LCn3, 2 ALA,  
1 omega-6, 1 
PUFA, 1 both 












Notes: yr = year, N = recruited assuming normal cognition, I = recruited assuming impaired cognition, MoH = Moderate or High summary risk of bias, 
Low = low summary risk of bias, m = months, wks = weeks, LA: Linoleic acid, MUFA: monounsaturated fatty acid, nr = not reported  
SR of omega-3, omega-6 & total PUFA for cognition, page 30 
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